Literature DB >> 182242

Determination of human apolipoprotein E by electroimmunoassay.

M D Curry, W J McConathy, P Alaupovic, J H Ledford, M Popović.   

Abstract

1. Apolipoprotein E ("arginine-rich" polypeptide) was isolated from delipidized human very low density lipoproteins by agarose column chromatography in the presence of 6 M guanidine-hydrochloride. 2. An electroimmunoassay ("rocket" electrophoresis) is described for quantitative determination of human serum apolipoprotein E. Purified apolipoprotein E was used for the preparation of monospecific antisera and standardization of assay. This sensitive, specific, rapid (time required for the completion of the assay is 5 h) and precise (the within- and between-assay coefficients of variation are 5 and 8%, respectively) assay is applicable to measurement of apolipoprotein E in whole serum and density classes. The results correlated well with those obtained by radial immunodiffusion (r = 0.85). 3. Serum apolipoprotein E levels of normal subjects and hyperlipoproteinemic phenotypes IIa, IIb and IV were the same (10 to 16 mg/100 ml). In contrast, patients with type III and V hyperlipoproteinemias had markedly elevated serum apolipoprotein E levels )27 and 25 mg/100 ml, respectively). The apolipoprotein E in serum of normolipidemic subjects was equally distributed among three major lipoprotein density classes: d less than 1.030 g/ml (27%), d 1.030-1.063 g/ml (36%)and d 1.063-1.21 g/ml (37%).

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 182242     DOI: 10.1016/0005-2795(76)90078-7

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  14 in total

1.  The composition and metabolism of high density lipoprotein subfractions.

Authors:  E J Schaefer; D M Foster; L L Jenkins; F T Lindgren; M Berman; R I Levy; H B Brewer
Journal:  Lipids       Date:  1979-05       Impact factor: 1.880

2.  Evidence for the lipoprotein heterogeneity of human plasma high density lipoproteins isolated by three different procedures.

Authors:  A Suenram; W J McConathy; P Alaupovic
Journal:  Lipids       Date:  1979-05       Impact factor: 1.880

3.  Apolipoprotein E synthesis in human kidney, adrenal gland, and liver.

Authors:  M L Blue; D L Williams; S Zucker; S A Khan; C B Blum
Journal:  Proc Natl Acad Sci U S A       Date:  1983-01       Impact factor: 11.205

4.  Lipid and apolipoprotein levels during therapy with pinacidil combined with hydrochlorothiazide.

Authors:  C N Corder; M R Goldberg; P A Alaupovic; M D Price; S S Furste
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

5.  Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III.

Authors:  C S Wang; W J McConathy; H U Kloer; P Alaupovic
Journal:  J Clin Invest       Date:  1985-02       Impact factor: 14.808

6.  Radioimmunoassay of human arginine-rich apolipoprotein, apoprotein E. Concentration in blood plasma and lipoproteins as affected by apoprotein E-3 deficiency.

Authors:  R J Havel; L Kotite; J L Vigne; J P Kane; P Tun; N Phillips; G C Chen
Journal:  J Clin Invest       Date:  1980-12       Impact factor: 14.808

7.  Radioimmunoassay studies of human apolipoprotein E.

Authors:  C B Blum; L Aron; R Sciacca
Journal:  J Clin Invest       Date:  1980-12       Impact factor: 14.808

8.  Radioimmunoassay of human apolipoprotein CII. A study in normal and hypertriglyceridemic subjects.

Authors:  M L Kashyap; L S Srivastava; C Y Chen; C G Perisutti; M Campbell; R F Lutmer; C J Glueck
Journal:  J Clin Invest       Date:  1977-07       Impact factor: 14.808

9.  Increased prevalence of apolipoprotein E4 in type V hyperlipoproteinemia.

Authors:  G Ghiselli; E J Schaefer; L A Zech; R E Gregg; H B Brewer
Journal:  J Clin Invest       Date:  1982-08       Impact factor: 14.808

10.  Isolation and characterization of apolipoprotein B-48 and B-100 very low density lipoproteins from type III hyperlipoproteinemic subjects.

Authors:  R W Milne; P K Weech; L Blanchette; J Davignon; P Alaupovic; Y L Marcel
Journal:  J Clin Invest       Date:  1984-03       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.